XAIR (Beyond Air) Valuation Rank


XAIR Beyond Air Inc XAIR
25 GF Score
Price $0.46
GF Value $6.66
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Beyond Air Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Beyond Air Valuation Rank Related Terms

XAIR
25GF Score
Beyond Air Inc XAIR
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Beyond Air (XAIR) Overvalued in 2026?

Based on GuruFocus' analysis, Beyond Air stock appears to be undervalued. The current stock price of $0.46 is trading 93.1% below its estimated GF Value™ of $6.66. GuruFocus considers Beyond Air to be Possible Value Trap.

Key valuation signals for XAIR:

  • Valuation Rank:
  • GF Value™: $6.66 vs. price of $0.46 (93.1% below fair value)
  • GF Score™: 25/100 with 7 warning signs

No single metric tells the full story. See the XAIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beyond Air Business Description

Address 900 Stewart Avenue, Suite 301, Garden City, New York, NY, USA, 11530
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
25GF Score

Get the complete analysis for XAIR

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.46
Price
$6.66
GF Value